PubMed HealthSearch

Biomedical subjects

S F Hurley

Publications and source records attributed to S F Hurley.

15 recordsLinked to original sources

Effectiveness, costs, and cost-effectiveness of recruitment strategies for a mammographic screening program to detect breast cancer.

BACKGROUND AND PURPOSE: Since effective and affordable recruitment methods are essential for the widespread implementation of mammographic screening for detection of breast cancer, we studied the effectiveness, the costs, and the cost-effectiveness of various recruitment strategies in the population targeted by a pilot Australian program that offered free mammography screening between 1988 and 1990. METHODS: We evaluated three public recruitment strategies--local newspaper articles, community promotion, and promotion to physicians--and five personal strategies--invitation letters with or without specified appointment times, either alone or with a follow-up letter, or telephone call to nonattenders. The effectiveness of public recruitment strategies was estimated from monthly attendance rates by Poisson regression analysis, while the probability of attendance in response to personal strategies was calculated using logistic regression analysis. Costs were determined by resource usage studies. The cost-effectiveness ratios for personal strategies were determined using decision analysis. RESULTS: The costs in 1988-1989 Australian dollars per woman recruited were $22 for local newspaper articles and $106 for community promotion. No detectable increase in attendance resulted from promotion to physicians. When the cost of reserving an appointment was considered, the most cost-effective personal recruitment strategy was an invitation letter without a specified appointment time, followed by a second letter to nonattenders. This strategy recruited 35.6% of women in the sample targeted and cost $10.52 per attendee. In comparison, the most effective personal recruitment strategy was a letter with a specified appointment time followed by a second letter to nonattenders, which recruited 44.1% of women at an average cost of $19.99 and a marginal cost of $59.71 per additional attendee. CONCLUSIONS: Personal recruitment strategies were more cost-effective than public strategies. The most cost-effective personal strategy was an invitation letter without a specified appointment time, followed by a second letter to nonattenders.

Australia

Linking prescription and patient-identifying data: a pilot study.

OBJECTIVE: To link a Pharmaceutical Benefits Scheme (PBS) prescription data set with patient-identifying data held by the Health Insurance Commission (HIC) and to then determine the prevalence of prescribing of cardiovascular drugs, non-steroidal anti-inflammatory drugs, hypnotics and minor tranquillizers, and diuretics (prescribed without other cardiovascular drugs) by age and sex in two defined populations. DESIGN: Prescription data for a three-month period in 1985 were matched with patient-identifying information to obtain a database which included the patient's age, sex and an identifying number, for each prescription record. The percentages of the population taking a drug from each of the drug categories mentioned above were then determined and the effect of age, sex and region of residence on prescribing prevalence was investigated using logistic regression analysis. SETTING: Two rural regions of Australia with a total population of 65,087 residents. MEASUREMENTS AND MAIN RESULTS: Of the 101,383 prescriptions dispensed over the period 96% could be matched with HIC information. In the two regions combined, the percentages of the population taking a cardiovascular drug, non-steroidal anti-inflammatory drug, hypnotic or minor tranquilizer, or diuretic (without other cardiovascular drugs) were 10.4%, 5.8%, 3.5% and 2.5%, respectively. Prescribing rates were higher for females than males, increased with age and varied between the two regions. Approximately 5% of women aged 30-39 years were taking diuretics without other cardiovascular drugs, compared with only 0.2% of men in the same age group. CONCLUSIONS: This pilot study illustrates the use of a patient-identified prescription database for drug utilisation review, therapeutic audit and hypothesis generation.

Adult

The cost of breast cancer recurrences.

Information about the costs of recurrent breast cancer is potentially important for targeting cost containment strategies and analysing the cost-effectiveness of breast cancer control programmes. We estimated these costs by abstracting health service and consumable usage data from the medical histories of 128 patients, and valuing each of the resources used. Resource usage and costs were summarised by regarding the recurrence as a series of episodes which were categorised into five anatomical site-based groups according to the following hierarchy: visceral, central nervous system (CNS), bone, local and other. Hospital visits and investigations comprised 78% of total costs for all episodes combined, and there were significant differences between the site-based groups in the frequency of hospital visits and most investigations. Total costs were most accurately described by separate linear regression models for each group, with the natural logarithm of the cost of the episode as the dependent variable, and predictor variables including the duration of the episode, duration squared, duration cubed and a variable indicating whether the episode was fatal. Visceral and CNS episodes were associated with higher costs than the other groups and were more likely to be shorter and fatal. A fatal recurrence of duration 15.7 months (the median for our sample) was predicted to cost $10,575 (Aus + 1988; or 4,877 pounds). Reduction of the substantial costs of recurrent breast cancer is likely to be a sizable economic benefit of adjuvant systemic therapy and mammographic screening. We did not identify any major opportunities for cost containment during the management of recurrences.

Adult

Personal costs incurred by women attending a mammographic screening programme.

A survey of the personal costs (travel and time) incurred by 150 randomly selected women attending a mammographic screening programme indicated that 74% travelled by car and 78 (52%) were accompanied by another person. Of the 78 accompanying persons 16 also had a breast x-ray. Fifteen women in the survey and 10 of the unscreened accompanying persons had taken leave from work to attend the programme, and this leave was unpaid for five women and two unscreened accompanying persons. The mean travel costs, out-of-pocket expenses, and opportunity costs per attendance were $6.45, $8.14, and $13.75, respectively. The personal costs involved in attending a screening programme appear to be substantial and may deter women from attending.

Aged

Use of antiasthmatic drugs in Australia.

Bronchodilator prescription and sales data for Australia from 1975 to 1986 were analysed. Inhaled beta-agonists were the most commonly prescribed antiasthmatic agents in 1986, followed by sustained-release theophylline and inhaled corticosteroids. Marked increases in prescription sales of these three drug groups over the period were noted. We estimate that non-prescription sales of salbutamol inhalers increased by 410% between 1980 and 1986 (P less than 0.01). Prescribing rates by general practitioners for beta-agonists, sustained-release theophylline and inhaled corticosteroids increased from 1979 to 1986. Prescribing rates of beta-agonists were highest for persons aged 1-11 years and 55 years and over, and increased markedly for children aged 1-11 years over the period. For sustained-release theophylline, prescribing rates were highest for persons 55 years and over. The difficulties in postulating possible relationships between prescribing trends and asthma mortality are discussed.

Administration, Inhalation

Trends in prescribing of antihypertensive drugs in Australia, 1977-1987.

Prescribing of hypotensive agents, beta-blockers and diuretics was analysed using data from the Pharmaceutical Benefits Scheme, adjusted to reflect prescribing for hypertension, over 1977-1987. Prescribing of these three drug groups combined increased by approximately 50% over the period. Notable trends were decreased prescribing of bendrofluazide, chlorothiazide and methyldopa and increased prescribing of hydrochlorothiazide with amiloride, atenolol, metoprolol and prazosin, and, most recently, captopril and enalapril. The increase in prescribing of drugs for hypertension, combined with the choice of more expensive drugs, has resulted in a substantial increase in the drug costs associated with treating hypertension.

Adrenergic beta-Antagonists

Patterns of surgical treatment of breast cancer in Victoria.

We analysed data on admissions to Victorian public hospitals for surgical treatment of breast cancer over the period July 1985 to December 1988. Of the 2993 women admitted, 28.7% received breast-preserving surgery. The probability of a woman being treated conservatively was dependent on age, with women aged less than 50 or more than 70 years more likely to receive breast-preserving surgery than women aged 50-69. There was an age-specific change, of marginal statistical significance, in the proportion of women receiving breast-preserving surgery over the period. The public hospitals admissions database is a potentially useful means of monitoring patterns of surgical treatment.

Adult

A comparison of the accuracy of a least squares regression, a Bayesian, Chiou's and the steady-state clearance method of individualising theophylline dosage.

We compared a least squares regression method, used prospectively to individualise the intravenous aminophylline and oral theophylline dosage of 48 patients, with 3 other pharmacokinetic methods - Chiou's, the steady-state clearance and the Bayesian - used retrospectively to analyse the same patient data. Methods were compared on the basis of the similarity of their parameter estimates and the accuracy with which serum concentrations during subsequent intravenous and oral therapy could be forecast, assuming each method's parameter estimates. The least squares and Bayesian programs were able to fit data from all but 4 and 2 patients, respectively. Mean absolute prediction errors were of the order of 20% for serum concentrations during intravenous therapy, and of the order of 40% for serum concentrations during oral therapy. The accuracy of the least squares, Bayesian and steady-state clearance methods were similar, but the accuracy of Chiou's method was comparable only when the 2 serum concentrations needed for the method were measured between 11 and 17 hours apart; an interval which corresponds to the 1.0 to 1.5 half-lives previously suggested as desirable for implementation of the Chiou method.

Adult

A randomized controlled clinical trial of pharmacokinetic theophylline dosing.

Ninety-one patients admitted to hospital with acute air-flow obstruction and requiring theophylline therapy were randomly assigned to either a monitored or a control group. Intravenously administered and subsequent orally administered theophylline dosages for patients in the monitored group were adjusted daily on the basis of each patients's estimated theophylline clearance; dosages for control patients were determined by attending physicians, using knowledge of theophylline serum concentrations. During intravenous therapy, fewer monitored than control patients had serum theophylline concentrations in the toxic range (18.9 versus 37.8%, p = 0.04), and during subsequent oral therapy more monitored than control patients had serum theophylline concentrations in the therapeutic range (71.1 versus 44.4%, p = 0.018). There was a trend for peak expiratory flow rates to normalize more quickly in monitored patients, and their mean duration of hospital stay was shorter (6.3 versus 8.7 days, p = 0.029). Two patients in the control group died; both had theophylline concentrations above 25 micrograms/ml and clinical toxicity. No serious side effects were observed in the monitored group. With pharmacokinetic individualization of theophylline dosage, more patients achieved serum concentrations in the therapeutic range, and there was a tendency for more rapid clinical improvement.

Administration, Oral

Trends in Australian mortality of asthma, 1979-1985.

Trends in Australian mortality rates that have been ascribed to asthma and to non-tuberculous, non-malignant respiratory diseases were examined for the period 1979-1985. Mortality rates of asthma and respiratory diseases increased substantially from 1979 to 1985, and in the case of asthma, the crude death rate in 1985 was higher than at the peak of the "epidemic" of the 1960s. The increase in mortality of asthma was most pronounced in those of greater than 60 years of age (from 11.5 per 100,000 such population in 1979 to 22.9 per 100,000 such population in 1985). Asthma mortality rates in five- to 34-year-old persons increased, although there were marked yearly fluctuations, and deaths of asthma in this age-group comprised only a small percentage (13% in 1985) of all deaths of asthma. Reasons that are considered for the rising death rate of asthma include changes in diagnostic fashion; an increase in the incidence or a change in the natural history of asthma; and an increased case fatality rate. With the presently-available data, it is not possible to distinguish among these possible explanations.

Adolescent